On 26 February 2013, the French Competition Authority ("Autorité de la concurrence") announced the launch of a pharma sector inquiry. The Autorité's main goal is to address the cost of prescription medicines for social security, the high prices of non-reimbursable medicines, and the low level of generic competition in France. The inquiry will focus on the distribution of medicinal products by pharmaceutical companies, wholesalers and pharmacists and will not touch upon patent settlement agreements. The Autorité will also examine the issue of online sale of medicines.
Click here to download PDF.
This publication is provided for your convenience and does not constitute legal advice. This publication is protected by copyright.
© 2013 White & Case LLP